These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 22771009)

  • 21. Hit-to-lead studies on benzimidazole inhibitors of ITK: discovery of a novel class of kinase inhibitors.
    Snow RJ; Abeywardane A; Campbell S; Lord J; Kashem MA; Khine HH; King J; Kowalski JA; Pullen SS; Roma T; Roth GP; Sarko CR; Wilson NS; Winters MP; Wolak JP; Cywin CL
    Bioorg Med Chem Lett; 2007 Jul; 17(13):3660-5. PubMed ID: 17499505
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Docking of protein kinase B inhibitors: implications in the structure-based optimization of a novel scaffold.
    Hernández-Campos A; Velázquez-Martínez I; Castillo R; López-Vallejo F; Jia P; Yu Y; Giulianotti MA; Medina-Franco JL
    Chem Biol Drug Des; 2010 Sep; 76(3):269-76. PubMed ID: 20572809
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Discovery and optimization of a series of benzothiazole phosphoinositide 3-kinase (PI3K)/mammalian target of rapamycin (mTOR) dual inhibitors.
    D'Angelo ND; Kim TS; Andrews K; Booker SK; Caenepeel S; Chen K; D'Amico D; Freeman D; Jiang J; Liu L; McCarter JD; San Miguel T; Mullady EL; Schrag M; Subramanian R; Tang J; Wahl RC; Wang L; Whittington DA; Wu T; Xi N; Xu Y; Yakowec P; Yang K; Zalameda LP; Zhang N; Hughes P; Norman MH
    J Med Chem; 2011 Mar; 54(6):1789-811. PubMed ID: 21332118
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Discovery of novel purine derivatives with potent and selective inhibitory activity against c-Src tyrosine kinase.
    Huang H; Ma J; Shi J; Meng L; Jiang H; Ding J; Liu H
    Bioorg Med Chem; 2010 Jul; 18(13):4615-24. PubMed ID: 20570525
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Conformationally-restricted cyclic sulfones as potent and selective mTOR kinase inhibitors.
    Liu KK; Bailey S; Dinh DM; Lam H; Li C; Wells PA; Yin MJ; Zou A
    Bioorg Med Chem Lett; 2012 Aug; 22(15):5114-7. PubMed ID: 22765900
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Identification and structure-activity relationship of 2-morpholino 6-(3-hydroxyphenyl) pyrimidines, a class of potent and selective PI3 kinase inhibitors.
    Pecchi S; Renhowe PA; Taylor C; Kaufman S; Merritt H; Wiesmann M; Shoemaker KR; Knapp MS; Ornelas E; Hendrickson TF; Fantl W; Voliva CF
    Bioorg Med Chem Lett; 2010 Dec; 20(23):6895-8. PubMed ID: 21035331
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Interaction profiles of protein kinase-inhibitor complexes and their application to virtual screening.
    Chuaqui C; Deng Z; Singh J
    J Med Chem; 2005 Jan; 48(1):121-33. PubMed ID: 15634006
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The Rational Design of Selective Benzoxazepin Inhibitors of the α-Isoform of Phosphoinositide 3-Kinase Culminating in the Identification of (S)-2-((2-(1-Isopropyl-1H-1,2,4-triazol-5-yl)-5,6-dihydrobenzo[f]imidazo[1,2-d][1,4]oxazepin-9-yl)oxy)propanamide (GDC-0326).
    Heffron TP; Heald RA; Ndubaku C; Wei B; Augistin M; Do S; Edgar K; Eigenbrot C; Friedman L; Gancia E; Jackson PS; Jones G; Kolesnikov A; Lee LB; Lesnick JD; Lewis C; McLean N; Mörtl M; Nonomiya J; Pang J; Price S; Prior WW; Salphati L; Sideris S; Staben ST; Steinbacher S; Tsui V; Wallin J; Sampath D; Olivero AG
    J Med Chem; 2016 Feb; 59(3):985-1002. PubMed ID: 26741947
    [TBL] [Abstract][Full Text] [Related]  

  • 29. 4-methylpteridinones as orally active and selective PI3K/mTOR dual inhibitors.
    Liu KK; Bagrodia S; Bailey S; Cheng H; Chen H; Gao L; Greasley S; Hoffman JE; Hu Q; Johnson TO; Knighton D; Liu Z; Marx MA; Nambu MD; Ninkovic S; Pascual B; Rafidi K; Rodgers CM; Smith GL; Sun S; Wang H; Yang A; Yuan J; Zou A
    Bioorg Med Chem Lett; 2010 Oct; 20(20):6096-9. PubMed ID: 20817449
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Discovery and characterization of non-ATP site inhibitors of the mitogen activated protein (MAP) kinases.
    Comess KM; Sun C; Abad-Zapatero C; Goedken ER; Gum RJ; Borhani DW; Argiriadi M; Groebe DR; Jia Y; Clampit JE; Haasch DL; Smith HT; Wang S; Song D; Coen ML; Cloutier TE; Tang H; Cheng X; Quinn C; Liu B; Xin Z; Liu G; Fry EH; Stoll V; Ng TI; Banach D; Marcotte D; Burns DJ; Calderwood DJ; Hajduk PJ
    ACS Chem Biol; 2011 Mar; 6(3):234-44. PubMed ID: 21090814
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Homology modeling and virtual screening approaches to identify potent inhibitors of slingshot phosphatase 1.
    Park H; Park SY; Ryu SE
    J Mol Graph Model; 2013 Feb; 39():65-70. PubMed ID: 23220283
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Structure-based optimization of morpholino-triazines as PI3K and mTOR inhibitors.
    Poulsen A; Williams M; Nagaraj HM; William AD; Wang H; Soh CK; Xiong ZC; Dymock B
    Bioorg Med Chem Lett; 2012 Jan; 22(2):1009-13. PubMed ID: 22197143
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Fragment based discovery of a novel and selective PI3 kinase inhibitor.
    Hughes SJ; Millan DS; Kilty IC; Lewthwaite RA; Mathias JP; O'Reilly MA; Pannifer A; Phelan A; Stühmeier F; Baldock DA; Brown DG
    Bioorg Med Chem Lett; 2011 Nov; 21(21):6586-90. PubMed ID: 21925880
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The crossregulation between ERK and PI3K signaling pathways determines the tumoricidal efficacy of MEK inhibitor.
    Won JK; Yang HW; Shin SY; Lee JH; Heo WD; Cho KH
    J Mol Cell Biol; 2012 Jun; 4(3):153-63. PubMed ID: 22561840
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Quinazolines with intra-molecular hydrogen bonding scaffold (iMHBS) as PI3K/mTOR dual inhibitors.
    Liu KK; Huang X; Bagrodia S; Chen JH; Greasley S; Cheng H; Sun S; Knighton D; Rodgers C; Rafidi K; Zou A; Xiao J; Yan S
    Bioorg Med Chem Lett; 2011 Feb; 21(4):1270-4. PubMed ID: 21269826
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Imidazo[1,2-a]pyrazines as novel PI3K inhibitors.
    Martínez González S; Hernández AI; Varela C; Rodríguez-Arístegui S; Alvarez RM; García AB; Lorenzo M; Rivero V; Oyarzabal J; Rabal O; Bischoff JR; Albarrán M; Cebriá A; Alfonso P; Link W; Fominaya J; Pastor J
    Bioorg Med Chem Lett; 2012 Mar; 22(5):1874-8. PubMed ID: 22325943
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Discovery and SAR exploration of a novel series of imidazo[4,5-b]pyrazin-2-ones as potent and selective mTOR kinase inhibitors.
    Mortensen DS; Perrin-Ninkovic SM; Harris R; Lee BG; Shevlin G; Hickman M; Khambatta G; Bisonette RR; Fultz KE; Sankar S
    Bioorg Med Chem Lett; 2011 Nov; 21(22):6793-9. PubMed ID: 21978683
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Synthesis, biological evaluation, and molecular docking studies of 1,3,4-thiadiazol-2-amide derivatives as novel anticancer agents.
    Yang XH; Xiang L; Li X; Zhao TT; Zhang H; Zhou WP; Wang XM; Gong HB; Zhu HL
    Bioorg Med Chem; 2012 May; 20(9):2789-95. PubMed ID: 22503364
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Crosstalk between the PI3K/mTOR and MEK/ERK pathways involved in the maintenance of self-renewal and tumorigenicity of glioblastoma stem-like cells.
    Sunayama J; Matsuda K; Sato A; Tachibana K; Suzuki K; Narita Y; Shibui S; Sakurada K; Kayama T; Tomiyama A; Kitanaka C
    Stem Cells; 2010 Nov; 28(11):1930-9. PubMed ID: 20857497
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A combination strategy to inhibit Pim-1: synergism between noncompetitive and ATP-competitive inhibitors.
    Mori M; Tintori C; Christopher RS; Radi M; Schenone S; Musumeci F; Brullo C; Sanità P; Delle Monache S; Angelucci A; Kissova M; Crespan E; Maga G; Botta M
    ChemMedChem; 2013 Mar; 8(3):484-96. PubMed ID: 23436791
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.